Pharmaceutical Packaging & Labeling Services in European Union: Market Size, Businesses & Forecast 2026

The European Union pharmaceutical packaging and labeling services sector encompasses critical post-production processes, including specialized containment, blister packing, custom cartoning, serialization, and smart labeling. The industry is directly supported by Europe's robust pharmaceutical export sector, which posted a record-high trade surplus of €221 billion in 2025 according to Eurostat. Driven by intense serialization mandates under the EU Falsified Medicines Directive and upcoming environmental packaging regulations, the sector is rapidly transitioning toward high-barrier biopolymers, smart RFID tags, and closed-loop glass systems.

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Pharmaceutical Packaging & Labeling Services in European Union industry cover?

The pharmaceutical packaging and labeling services industry in the European Union comprises outsourced and in-house activities designed to ensure the sterile containment, security, and compliant distribution of medicinal products. Primary packaging activities deal with direct-contact materials like blisters, prefilled syringes, and vials, which must comply with strict Good Manufacturing Practice (GMP) standards. Secondary and tertiary packaging involve cartoning, smart-labeling, and heavy shipping preparation, adding layers of protection and compliance data.

• •Primary packaging elements (blisters, vials) prevent physical and chemical contamination of sensitive drug formulas.
• •Secondary packaging functions as the main vector for required patient communication, serial numbers, and tamper-evident mechanisms.
• •Under NACE classification, primary chemical-contact packaging is structurally integrated under pharmaceutical manufacturing, while separate contract packaging services sit under distinct business support divisions.

Who operates in the industry and how is it structured?

The market is populated by a blend of dedicated Contract Packaging Organizations (CPOs), integrated Contract Development and Manufacturing Organizations (CDMOs), and in-house packaging units of multinational pharmaceutical corporations. CPOs provide crucial flexibility, enabling drug innovators to scale up production without dedicating significant capital to highly specialized machinery. Operators typically establish localized facilities across Europe's primary pharmaceutical clusters to minimize transport friction and secure strict supply-chain continuity.

• •Integrated CDMOs bundle packaging as an end-to-end service alongside chemical synthesis and drug formulation.
• •Local specialized CPOs focus purely on fast-turnaround secondary packaging, clinical trial labeling, and multi-language country adaptation.
• •Manufacturing clusters in Germany, France, Italy, and Ireland anchor the majority of European contract packaging capacities.

What drives demand in the industry?

Demand is heavily driven by the sustained rise in European biopharmaceutical manufacturing and specialized injectables, which require advanced primary containment such as cyclic olefin copolymer cartridges and sterile prefilled syringes. Furthermore, strict regional regulatory mandates concerning anti-counterfeiting and green supply chains force pharmaceutical firms to continuously redesign their packaging formats. The growing complexity of multi-lingual regulatory approvals across EU member states also accelerates the outsourcing of late-stage customization and local labeling services.

• •Biologics accounted for over 30% of new molecular entities approved by the European Medicines Agency (EMA) in 2024, raising demand for advanced parenteral containment.
• •The expansion of home-administered autoinjectors and personalized medicine fuels demand for smart, patient-centric packaging formats.
• •Sustained international exports of EU medicinal products, which grew by 16% to reach a €221 billion trade surplus in 2025 (Eurostat), guarantee consistent industrial volumes.

Who are the notable companies in the industry?

The European landscape features highly competitive multinational packaging giants alongside specialized clinical packaging providers. Companies compete heavily on engineering precision, material barrier sciences, digital tracking integrations, and the breadth of their local European manufacturing footprints. Significant capital is routinely invested into high-barrier flexible foils, glass vial furnaces, and automated serialization lines to maintain regulatory compliance and secure market share.

• •Gerresheimer AG (headquartered in Germany) is an industry leader in primary glass and plastic containment, generating stable revenue and operating dozens of facilities globally.
• •Amcor plc (headquartered in Switzerland) operates a massive European footprint specializing in high-barrier circular-economy polymer films and recyclable blister packs.
• •Schott Pharma (Schott AG, Germany) is highly specialized in advanced drug containment, utilizing premium Type I borosilicate glass and cyclic olefin polymers for high-value biologics.
• •CCL Industries, Inc. (headquartered in Canada) dominates high-volume European pharmaceutical labeling through its functional multi-layer booklet labels and anti-counterfeit smart strips.

What are the recent trends and outlook?

The European packaging sector is currently shaped by aggressive transitions toward circular economy materials and the integration of digital, smart-tracking solutions. Manufacturers are actively replacing polyvinyl chloride (PVC) with recyclable polyethylene terephthalate (PET) and biopolymers to align with looming EU environmental packaging mandates. Concurrently, the adoption of digital smart blisters, RFID-enabled vials, and near-field communication (NFC) labels is expanding to improve clinical adherence and end-to-end trace-and-trace monitoring.

• •In October 2024, Liveo Research and Bayer successfully introduced a PET blister packaging that eliminated PVC and reduced carbon footprint by 38%.
• •In January 2025, LOG Pharma introduced its Eco Line barrier bottles at Pharmapack Europe, reducing packaging weight by up to 30%.
• •Volatile energy costs for natural-gas fired glass furnaces (operating at 1,500 °C) are driving packaging firms to invest in hybrid electric melting technologies.

How is the industry regulated?

Compliance within the EU pharmaceutical packaging market is extraordinarily rigid, governed closely by safety, identification, and ecological mandates. Every prescription package distributed across the EU must strictly comply with the Falsified Medicines Directive (FMD), which requires a unique 2D data matrix identifier and a robust physical tamper-evident feature. Additionally, packaging operators must prepare for tightening environmental guidelines under the upcoming EU Packaging and Packaging Waste Regulation (PPWR).

• •The Falsified Medicines Directive (Directive 2011/62/EU) mandates end-to-end serialization and tamper-evidence for virtually all prescription medications.
• •The upcoming PPWR enforcement post-2028 places strict recyclable and recycled-content targets on plastic packaging materials.
• •Packaging processes must adhere strictly to EU Guidelines for Good Manufacturing Practice (GMP) Annex 1 (sterile drug products) and Annex 16 (certification by a Qualified Person).

Government, statistical and trade sources used for this Claight analysis.

• Eurostat - International trade in medicinal and pharmaceutical products (2026 Edition) ·
• European Medicines Agency (EMA) Guidelines ·
• European Federation of Pharmaceutical Industries and Associations (EFPIA)